

IN THE CLAIMS:

1. (original) Oligodeoxynucleotides for stimulating an adjuvant or treating immune-related diseases, presented in General Formula:

[General Formula]: HKCGTTCRTGTCSGM (SEQ ID NO: 1)

wherein, R represents A or G; S represents C or G; H represents A, T or C; K represents G or T; and M represents C or A.

2. (original) The oligodeoxynucleotides for stimulating an adjuvant or treating immune-related diseases according to the claim 1, wherein the oligonucleotides further comprise five nucleotides, presented in following General Formula, at a 5'-terminal end and a 3'-terminal end:

[General Formula]: DKMHKCGTTCRTGTCSGMYK (SEQ ID NO: 2)

wherein, R represents A or G; S represents C or G; H represents A, T or C; K represents G or T; D represents A, G or T; M represents C or A; M represents C or A; and Y represents C or T.

3. (original) The oligodeoxynucleotides according to any of the claims 1 and 2, wherein the oligodeoxynucleotides protect normal immune cells when the radiotherapy is applied.

4. (original) The oligodeoxynucleotides according to any of the claims 1 and 2, wherein the oligodeoxynucleotides treat or prevent skin diseases.

5. (original) The oligodeoxynucleotides according to any of the claims 1 and 2, wherein the oligodeoxynucleotides maintain balances of various Th1/Th2 immune reactions.

6. (original) The oligodeoxynucleotides according to any of the claims 1 and 2, wherein the oligodeoxynucleotides have a phosphodiester bond or phosphorothioate bond between the nucleotides.

7. (original) The oligodeoxynucleotides according to any of the claims 1 and 2, wherein the oligonucleotides are selected from the group consisting of 5'-AGCAGCGTTCGTGTCCGCCT-3' (SEQ ID NO: 3), 5'-AGCAGCGTTCGTGTGCGCCT-3' (SEQ ID NO: 4), 5'-AGCAGCGTTCATGTCCGCCT-3' (SEQ ID NO: 5), 5'-AGCAGCGTTCGTGTCCGCCT-3' (SEQ ID NO: 6), 5'-GTATTCGTTCGTGTGTCGCCT-3' (SEQ ID NO: 7) and 5'-TGACTCGTTCGTGTGTCGCATG-3' (SEQ ID NO: 8).